Accolade (ACCD) Stock Forecast, Price Target & Predictions
ACCD Stock Forecast
Accolade stock forecast is as follows: an average price target of $14.81 (represents a 316.01% upside from ACCD’s last price of $3.56) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.
ACCD Price Target
The average price target for Accolade (ACCD) is $14.81 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $52.00 to $5.00. This represents a potential 316.01% upside from ACCD's last price of $3.56.
ACCD Analyst Ratings
According to 16 Wall Street analysts, Accolade's rating consensus is 'Buy'. The analyst rating breakdown for ACCD stock is 0 'Strong Buy' (0.00%), 10 'Buy' (62.50%), 6 'Hold' (37.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Accolade Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 28, 2024 | David Grossman | Stifel Nicolaus | $8.00 | $3.58 | 123.46% | 124.72% |
| Jun 28, 2024 | Richard Close | Canaccord Genuity | $13.00 | $6.39 | 103.44% | 265.17% |
| Jun 28, 2024 | Ryan MacDonald | Needham | $8.00 | $6.39 | 25.20% | 124.72% |
| Jun 28, 2024 | Jailendra Singh | Truist Financial | $9.00 | $6.39 | 40.85% | 152.81% |
| Jun 28, 2024 | Stephanie Davis | Barclays | $5.50 | $6.39 | -13.93% | 54.49% |
| Jun 28, 2024 | Gil Luria | D.A. Davidson | $5.00 | $6.39 | -21.75% | 40.45% |
| Apr 30, 2024 | Stan Berenshteyn | Wells Fargo | $10.00 | $8.19 | 22.10% | 180.90% |
| Oct 04, 2023 | Ricky Goldwasser | Morgan Stanley | $14.00 | $10.03 | 39.58% | 293.26% |
| Jun 30, 2023 | Ryan MacDonald | Needham | $17.00 | $13.61 | 24.91% | 377.53% |
| Jun 30, 2023 | Ryan MacDonald | Needham | $14.27 | $12.64 | 12.90% | 300.84% |
The latest Accolade stock forecast, released on Jun 28, 2024 by David Grossman from Stifel Nicolaus, set a price target of $8.00, which represents a 123.46% increase from the stock price at the time of the forecast ($3.58), and a 124.72% increase from ACCD last price ($3.56).
Accolade Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 7 |
| Avg Price Target | - | - | $8.36 |
| Last Closing Price | $3.56 | $3.56 | $3.56 |
| Upside/Downside | -100.00% | -100.00% | 134.83% |
In the current month, the average price target of Accolade stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Accolade's last price of $3.56. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 09, 2024 | Stephens | Buy | Buy | Hold |
| Oct 04, 2024 | Needham | Buy | Buy | Hold |
| Oct 04, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Oct 04, 2024 | Raymond James | Outperform | Outperform | Hold |
| Jun 28, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jun 28, 2024 | Needham | Buy | Buy | Hold |
| Jun 28, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Apr 30, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Feb 26, 2024 | Raymond James | Underperform | Underperform | Hold |
| Feb 26, 2024 | Wells Fargo | Buy | Buy | Hold |
Accolade's last stock rating was published by Stephens on Oct 09, 2024. The company gave ACCD a "Buy" rating, the same as its previous rate.
Accolade Financial Forecast
Accolade Revenue Forecast
| Mar 27 | Dec 26 | Aug 26 | May 26 | Mar 26 | Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Dec 21 | Aug 21 | May 21 | Mar 21 | Dec 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $96.86M | $93.23M | - | - | $87.64M | $85.53M | - | - | $73.29M | $59.53M | - | - | $36.79M | $35.89M |
| Avg Forecast | $174.46M | $136.69M | $133.68M | $136.88M | $160.36M | $121.94M | $120.52M | $121.71M | $142.39M | $106.00M | $104.87M | $105.95M | $123.91M | $96.16M | $94.09M | $90.82M | $99.44M | $87.53M | $82.86M | $81.98M | $91.58M | $75.89M | $70.37M | $55.67M | $56.64M | $36.25M | $34.62M | $34.14M |
| High Forecast | $177.49M | $139.06M | $136.00M | $139.26M | $163.15M | $124.06M | $122.62M | $123.82M | $145.27M | $106.80M | $104.95M | $106.32M | $123.91M | $96.64M | $95.72M | $92.40M | $101.17M | $89.05M | $84.54M | $83.64M | $93.44M | $77.43M | $71.80M | $56.80M | $57.79M | $36.99M | $35.33M | $34.83M |
| Low Forecast | $169.51M | $132.82M | $129.89M | $133.00M | $155.82M | $118.49M | $117.11M | $118.26M | $136.98M | $105.37M | $104.78M | $105.59M | $123.91M | $95.39M | $91.42M | $88.25M | $96.63M | $85.05M | $80.91M | $80.05M | $89.42M | $74.10M | $68.71M | $54.36M | $55.30M | $35.40M | $33.81M | $33.33M |
| # Analysts | 5 | 6 | 4 | 4 | 4 | 4 | 3 | 7 | 9 | 9 | 4 | 5 | 9 | 10 | 5 | 5 | 8 | 4 | 4 | 4 | 7 | 5 | 5 | 5 | 8 | 5 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.03% | - | - | 1.06% | 1.04% | - | - | 1.04% | 1.07% | - | - | 1.06% | 1.05% |
Accolade's average Quarter revenue forecast for Dec 23 based on 10 analysts is $96.16M, with a low forecast of $95.39M, and a high forecast of $96.64M. ACCD's average Quarter revenue forecast represents a -0.72% decrease compared to the company's last Quarter revenue of $96.86M (Aug 23).
Accolade EBITDA Forecast
| Mar 27 | Dec 26 | Aug 26 | May 26 | Mar 26 | Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Dec 21 | Aug 21 | May 21 | Mar 21 | Dec 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 6 | 4 | 4 | 4 | 4 | 3 | 7 | 9 | 9 | 4 | 5 | 9 | 10 | 5 | 5 | 8 | 4 | 4 | 4 | 7 | 5 | 5 | 5 | 8 | 5 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-20.38M | $-25.94M | - | - | $-34.47M | $-34.81M | - | - | $-63.41M | $-39.37M | - | - | $-10.96M | $-10.71M |
| Avg Forecast | $-49.74M | $-38.97M | $-38.11M | $-39.03M | $-45.72M | $-34.77M | $-34.36M | $-34.70M | $-40.60M | $-30.22M | $-29.90M | $-30.21M | $-14.20M | $-27.42M | $-26.83M | $-25.89M | $-12.91M | $-24.96M | $-9.82M | $-9.72M | $-11.73M | $-9.00M | $-8.34M | $-25.75M | $-6.71M | $-4.30M | $-9.04M | $-4.05M |
| High Forecast | $-48.33M | $-37.87M | $-37.03M | $-37.92M | $-44.43M | $-33.78M | $-33.39M | $-33.72M | $-39.05M | $-30.04M | $-29.87M | $-30.10M | $-11.36M | $-27.20M | $-26.07M | $-25.16M | $-10.32M | $-24.25M | $-9.59M | $-9.49M | $-9.39M | $-8.78M | $-8.15M | $-20.60M | $-6.56M | $-4.20M | $-7.23M | $-3.95M |
| Low Forecast | $-50.60M | $-39.65M | $-38.77M | $-39.70M | $-46.52M | $-35.37M | $-34.96M | $-35.30M | $-41.42M | $-30.45M | $-29.92M | $-30.31M | $-17.04M | $-27.55M | $-27.29M | $-26.34M | $-15.49M | $-25.39M | $-10.02M | $-9.91M | $-14.08M | $-9.18M | $-8.51M | $-30.90M | $-6.85M | $-4.38M | $-10.85M | $-4.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.76% | 1.00% | - | - | 3.51% | 3.58% | - | - | 7.60% | 1.53% | - | - | 1.21% | 2.65% |
undefined analysts predict ACCD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Accolade's previous annual EBITDA (undefined) of $NaN.
Accolade Net Income Forecast
| Mar 27 | Dec 26 | Aug 26 | May 26 | Mar 26 | Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Dec 21 | Aug 21 | May 21 | Mar 21 | Dec 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 6 | 4 | 4 | 4 | 4 | 3 | 7 | 9 | 9 | 4 | 5 | 9 | 10 | 5 | 5 | 8 | 4 | 4 | 4 | 7 | 5 | 5 | 5 | 8 | 5 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-32.83M | $-38.23M | - | - | $-46.52M | $-342.82M | - | - | $-62.36M | $-48.71M | - | - | $-15.37M | $-13.96M |
| Avg Forecast | $6.14M | $-19.48M | $-22.15M | $-25.62M | $6.91M | $-22.42M | $-23.72M | $-26.12M | $2.96M | $-26.42M | $-35.49M | $-38.43M | $-26.83M | $-35.80M | $-43.18M | $-49.44M | $-24.39M | $53.89M | $-57.56M | $-59.10M | $-22.17M | $-62.30M | $-47.15M | $-31.86M | $-7.34M | $-26.69M | $-12.68M | $-29.43M |
| High Forecast | $6.28M | $-18.77M | $-21.34M | $-24.68M | $7.06M | $-21.59M | $-22.85M | $-25.16M | $7.10M | $-22.16M | $-34.18M | $-37.02M | $-21.46M | $-28.80M | $-41.59M | $-47.62M | $-19.51M | $64.67M | $-55.80M | $-57.29M | $-17.74M | $-60.39M | $-45.71M | $-25.49M | $-7.12M | $-25.87M | $-10.14M | $-28.53M |
| Low Forecast | $5.91M | $-19.92M | $-22.65M | $-26.20M | $6.65M | $-22.93M | $-24.26M | $-26.71M | $-1.77M | $-29.83M | $-36.29M | $-39.30M | $-32.20M | $-40.47M | $-44.16M | $-50.56M | $-29.27M | $43.11M | $-59.08M | $-60.66M | $-26.61M | $-63.94M | $-48.40M | $-38.23M | $-7.53M | $-27.40M | $-15.22M | $-30.20M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.76% | 0.77% | - | - | 0.81% | 5.80% | - | - | 1.32% | 1.53% | - | - | 1.21% | 0.47% |
Accolade's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ACCD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Accolade SG&A Forecast
| Mar 27 | Dec 26 | Aug 26 | May 26 | Mar 26 | Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Dec 21 | Aug 21 | May 21 | Mar 21 | Dec 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 6 | 4 | 4 | 4 | 4 | 3 | 7 | 9 | 9 | 4 | 5 | 9 | 10 | 5 | 5 | 8 | 4 | 4 | 4 | 7 | 5 | 5 | 5 | 8 | 5 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $40.34M | $41.11M | - | - | $45.96M | $45.85M | - | - | $50.18M | $46.97M | - | - | $14.33M | $12.98M |
| Avg Forecast | $80.08M | $62.74M | $61.36M | $62.83M | $73.61M | $55.97M | $55.32M | $55.86M | $65.36M | $48.66M | $48.14M | $48.63M | $41.23M | $44.14M | $43.19M | $41.69M | $37.48M | $40.18M | $37.87M | $37.47M | $34.07M | $34.69M | $32.16M | $30.72M | $25.89M | $16.57M | $11.83M | $15.60M |
| High Forecast | $81.47M | $63.83M | $62.42M | $63.92M | $74.89M | $56.94M | $56.28M | $56.83M | $66.68M | $49.02M | $48.17M | $48.80M | $49.47M | $44.36M | $43.94M | $42.41M | $44.98M | $40.88M | $38.64M | $38.23M | $40.89M | $35.39M | $32.82M | $36.87M | $26.41M | $16.90M | $14.19M | $15.92M |
| Low Forecast | $77.81M | $60.96M | $59.62M | $61.05M | $71.52M | $54.39M | $53.75M | $54.28M | $62.87M | $48.37M | $48.10M | $48.46M | $32.98M | $43.79M | $41.96M | $40.51M | $29.98M | $39.04M | $36.98M | $36.59M | $27.26M | $33.87M | $31.41M | $24.58M | $25.28M | $16.18M | $9.46M | $15.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 0.99% | - | - | 1.21% | 1.22% | - | - | 1.56% | 1.53% | - | - | 1.21% | 0.83% |
Accolade's average Quarter SG&A projection for Dec 23 is $44.14M, based on 10 Wall Street analysts, with a range of $43.79M to $44.36M. The forecast indicates a 9.43% rise compared to ACCD last annual SG&A of $40.34M (Aug 23).
Accolade EPS Forecast
| Mar 27 | Dec 26 | Aug 26 | May 26 | Mar 26 | Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Dec 21 | Aug 21 | May 21 | Mar 21 | Dec 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 6 | 4 | 4 | 4 | 4 | 3 | 7 | 9 | 9 | 4 | 5 | 9 | 10 | 5 | 5 | 8 | 4 | 4 | 4 | 7 | 5 | 5 | 5 | 8 | 5 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.43 | $-0.52 | - | - | $-0.66 | $-4.92 | - | - | $-0.97 | $-0.84 | - | - | $-0.47 | $-0.30 |
| Avg Forecast | $0.08 | $-0.24 | $-0.28 | $-0.32 | $0.09 | $-0.28 | $-0.30 | $-0.33 | $0.04 | $-0.33 | $-0.44 | $-0.48 | $-0.11 | $-0.45 | $-0.54 | $-0.62 | $-0.41 | $-0.62 | $-0.72 | $-0.74 | $-0.42 | $-0.78 | $-0.59 | $-0.35 | $-0.09 | $-0.33 | $-0.40 | $-0.37 |
| High Forecast | $0.08 | $-0.23 | $-0.27 | $-0.31 | $0.09 | $-0.27 | $-0.29 | $-0.31 | $0.09 | $-0.28 | $-0.43 | $-0.46 | $-0.11 | $-0.36 | $-0.52 | $-0.59 | $-0.40 | $-0.60 | $-0.70 | $-0.72 | $-0.41 | $-0.75 | $-0.57 | $-0.34 | $-0.09 | $-0.32 | $-0.39 | $-0.36 |
| Low Forecast | $0.07 | $-0.25 | $-0.28 | $-0.33 | $0.08 | $-0.29 | $-0.30 | $-0.33 | $-0.02 | $-0.37 | $-0.45 | $-0.49 | $-0.12 | $-0.51 | $-0.55 | $-0.63 | $-0.42 | $-0.63 | $-0.74 | $-0.76 | $-0.43 | $-0.80 | $-0.60 | $-0.36 | $-0.09 | $-0.34 | $-0.41 | $-0.38 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | 0.84% | - | - | 0.92% | 6.67% | - | - | 1.65% | 2.39% | - | - | 1.17% | 0.81% |
According to undefined Wall Street analysts, Accolade's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ACCD previous annual EPS of $NaN (undefined).
Accolade Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACCD | Accolade | $3.56 | $14.81 | 316.01% | Buy |
| HCAT | Health Catalyst | $7.36 | $29.25 | 297.42% | Buy |
| EVH | Evolent Health | $11.31 | $40.86 | 261.27% | Buy |
| CMAX | CareMax | $0.74 | $2.60 | 251.35% | Hold |
| DH | Definitive Healthcare | $4.10 | $9.50 | 131.71% | Hold |
| CERT | Certara | $9.55 | $19.33 | 102.41% | Buy |
| PHR | Phreesia | $18.52 | $36.31 | 96.06% | Buy |
| PRVA | Privia Health Group | $20.79 | $33.82 | 62.67% | Buy |
| PINC | Premier | $22.23 | $33.25 | 49.57% | Hold |
| HSTM | HealthStream | $31.30 | $29.00 | -7.35% | Buy |